National Survey Shows 1 In 10 Children Use Cough/Cold OTCs Each Week
This article was originally published in The Tan Sheet
Executive Summary
A long-term study underscores possible risks from OTC pediatric cough/cold products and emphasizes the significance of FDA's ongoing review of the medicines' safety and efficacy for 2- to 11-year-old children
You may also be interested in...
Pediatric Cough/Cold “Reverse Switch” Will Not Increase Safety – CHPA
A potential "reverse switch" of pediatric cough/cold OTC drugs to prescription status would not address concerns about efficacy or misuse of the products, the Consumer Healthcare Products Association says
FDA Call For Pediatric Cough/Cold Input Signals New Rule Is A Long Way Off
FDA plans to revise monograph language for over-the-counter pediatric cough/cold products, but the agency is seeking input on some basic data questions first, indicating many steps will be taken before a rule can be finalized
FDA Working Group Considering Changes To OTC Cough/Cold Monograph
An FDA working group conducting a review of OTC cough and cold medicines for 2- to 11-year-old children will make recommendations this spring on actions the agency should take concerning use of the products for that age group, Office of Nonprescription Products officials said Jan. 17